Back to all studies
TerminatedNCT03669640

Effects of RO6889450 (Ralmitaront) for schizophrenia

This study was terminated in the United States, in Japan, in Spain, .... It is testing Effects of RO6889450 (Ralmitaront) for schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether RO6889450 may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive RO6889450, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Japan, in Spain, and in Ukraine.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: December 4, 2018
Recruitment status
Terminated
Enrollment listed in the registry
131
Sponsor
Hoffmann-La Roche
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Japan, Spain, ...
Age range
From 18 Years to 55 Years
Official registry ID
NCT03669640
Official title
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Japan · 5 sites
  • Kohnodai Hp., National Center for Global Health and Medicine
    Chiba
    Site status: Not listed — confirm with the team
  • National Hospital Organization Ryukyu Hospital
    Kunigami
    Site status: Not listed — confirm with the team
  • National Center of Neurology and Psychiatry
    Tokyo
    Site status: Not listed — confirm with the team
  • Seishinkai Okehazama Hospital Fujita Kokoro Care Center
    Toyoake
    Site status: Not listed — confirm with the team
  • Hiyoshi Hospital
    Yokohama
    Site status: Not listed — confirm with the team
Spain · 5 sites
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria
    Site status: Not listed — confirm with the team
  • Hospital Universitario Central de Asturias
    Oviedo, Principality of Asturias
    Site status: Not listed — confirm with the team
  • C.H. Regional Reina Sofia - PPDS
    Córdoba
    Site status: Not listed — confirm with the team
  • Hosp Univ Fundacion Alcorcon
    Madrid
    Site status: Not listed — confirm with the team
  • Complejo Asistencial Universitario de Salamanca ? H. Clinico
    Salamanca
    Site status: Not listed — confirm with the team
Ukraine · 7 sites
  • CNCE Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council
    Nove, Katerynoslav Governorate
    Site status: Not listed — confirm with the team
  • Communal Non-Commercial Enterprise of Kharkiv RC Regional clinical psychiatric hospital #3
    Kharkiv, Kharkiv Governorate
    Site status: Not listed — confirm with the team
  • Public NPE Kherson Regional Institution of Mental Care of Kherson RC
    Kherson, Kherson Governorate
    Site status: Not listed — confirm with the team
  • Municipal Non-Commercial Enterprise Odesa RMC for Mental Health of Odessa Regional Council
    Odesa, Kherson Governorate
    Site status: Not listed — confirm with the team
  • ME Dnipropetrovsk Regional Clinical Hospital n.a. I.I Mechnykov Dnipropetrovsk Regional Council
    Dnipro, KIEV Governorate
    Site status: Not listed — confirm with the team
  • Zakarpattia Regional Clinical Hospital n.a. Andrii Novak
    Uzhhorod, KIEV Governorate
    Site status: Not listed — confirm with the team
  • Communal NPE Vinnytsia Reg. Clin. Psychoneurolog. Hosp. n.a. O.I. Yushchenko of Vinnytsia RC
    Vinnytsia, Podolia Governorate
    Site status: Not listed — confirm with the team
United States · 28 sites
  • CITrials, Inc.
    Bellflower, California
    Site status: Not listed — confirm with the team
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California
    Site status: Not listed — confirm with the team
  • California Clinical Trials
    Glendale, California
    Site status: Not listed — confirm with the team
  • Synergy San Diego
    Lemon Grove, California
    Site status: Not listed — confirm with the team
  • Catalina Research Institute LLC - MRA
    Montclair, California
    Site status: Not listed — confirm with the team
  • CITrials, Inc.
    Riverside, California
    Site status: Not listed — confirm with the team
  • California Neuropsychopharmacology Clinical Research Institute, LLC
    San Diego, California
    Site status: Not listed — confirm with the team
  • Stanford University School of Medicine
    Stanford, California
    Site status: Not listed — confirm with the team
  • Collaborative Neuroscience Network Inc.
    Torrance, California
    Site status: Not listed — confirm with the team
  • Yale School of Medicine - CT Mental Health Center (CMHC) - Schizophrenia Research Clinic
    New Haven, Connecticut
    Site status: Not listed — confirm with the team
  • Innovative Clinical Research, Inc.
    Lauderhill, Florida
    Site status: Not listed — confirm with the team
  • Lifestream Behavioral Center
    Leesburg, Florida
    Site status: Not listed — confirm with the team
  • Advanced Research Institute of Miami
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Health Synergy Clinical Research
    Okeechobee, Florida
    Site status: Not listed — confirm with the team
  • Emory University
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • Northwestern University
    Chicago, Illinois
    Site status: Not listed — confirm with the team
  • CBH Health
    Gaithersburg, Maryland
    Site status: Not listed — confirm with the team
  • Precise Research Centers
    Flowood, Mississippi
    Site status: Not listed — confirm with the team
  • Psych Care Consultants Research
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • Millennium Psychiatric Associates, LLC
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • Manhattan Psychiatric Center; Psychopharmacology Research Unit
    New York, New York
    Site status: Not listed — confirm with the team
  • JPS Health Network
    Fort Worth, Texas
    Site status: Not listed — confirm with the team
  • Pillar Clinical Research LLC
    Garland, Texas
    Site status: Not listed — confirm with the team
  • Baylor College of Medicine
    Houston, Texas
    Site status: Not listed — confirm with the team
  • University Hills Clinical Research
    Irving, Texas
    Site status: Not listed — confirm with the team
  • The Solace Center
    Missouri City, Texas
    Site status: Not listed — confirm with the team
  • Psychiatry & Behavioral Center
    Richmond, Texas
    Site status: Not listed — confirm with the team
  • @ Health Texas
    Richmond, Texas
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT03669640. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving RO6889450, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 55 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Hoffmann-La Roche, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me